Scleroderma, Systemic Withdrawn Phase 2 Trials for Cefotaxime (DB00493)

Also known as: Systemic Scleroderma

IndicationStatusPhase
DBCOND0028174 (Scleroderma, Systemic)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs